Company / Cash & Equivalents
Traws Pharma, Inc. Cash & Equivalents History
FY2015-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$19.8M
FY2016
5-year range
-
FY2015-FY2016
Trend
-54.6%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$20M in FY2016.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, cash & equivalents decreased 54.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -42.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $19.8M | -54.6% |
| FY2015 | $43.6M | -27.4% |
As of FY2016 · SEC 10-K Annual Filings · Last checked Jun 28, 2026